Stay updated on Pembrolizumab Skin Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Skin Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Skin Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision: v3.4.3 update applied, replacing v3.4.2. This is a minor version update with no changes to the study information or user-facing features.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedRevision tag updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision: v3.4.1 replaces v3.4.0 as the page's version label. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No clinical trial content, eligibility criteria, or outcome measures appear to be altered.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a Locations section listing Georgia (Atlanta, Emory University/Winship Cancer Institute) as a study site. Removed the previous Georgia Locations heading and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check112 days agoChange DetectedThe page footer now displays Revision: v3.3.2, replacing the previous Revision: v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Skin Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Skin Cancer Clinical Trial page.